Data Scientist
About the job
- Experience developing deployable code and deploying models in product-focused development under an agile environment.
- Experience in production-ready software development.
- A track record of applying machine learning and deep learning approaches to solve commercial, industrial, or research problems.
- Experience with database mining, big data, and large-scale virtual screening.
- Excellent written and verbal communication skills.
- Experience working with multiple teams to drive alignment and results.
- Expertise in business analysis, data visualization, and data storytelling.
- Expertise with core data science languages such as Python and R, and familiarity with database systems such as SQL, NoSQL, graph, and time-series databases.
- Expertise with sensitive data in critical environments such as healthcare or defense.
- Expertise in most of the following areas: supervised learning, unsupervised learning, deep learning, large language models, reinforcement learning, federated learning, time-series forecasting, Bayesian statistics, and optimization.
- Comfort working in cloud and high-performance computing environments such as AWS, GCP, Databricks, and Apache Spark.
- Hands-on AI/ML modeling experience with complex datasets and a strong understanding of AI/ML theoretical foundations, CI/CD, and orchestration.
- Experience with data visualization technologies and libraries such as Tableau, Power BI, Streamlit, Plotly, and seaborn, or similar tools.
- Experience with enterprise-level application programming interfaces (APIs).
- Good knowledge of AI regulations.
- A PhD in mathematics, computer science, engineering, physics, statistics, economics, or a related quantitative discipline with strong coding skills, or a Master’s degree in a relevant domain.
- English and French language skills.
- Work with business teams to understand requirements and translate them into technical needs.
- Apply data science expertise in machine learning, deep learning, statistics, forecasting, and optimization to multiple AI projects and products.
- Gather and organize large, complex data assets; perform relevant analysis; and propose and implement data models for each business case.
- Build models, algorithms, simulations, and experiments by writing highly optimized code and using state-of-the-art machine learning technologies.
- Work across the full spectrum of activities, from conducting machine learning experiments to delivering production-ready models.
- Use data analysis, visualization, storytelling, and data technologies to scope, define, and deliver AI-based data products.
- Work with developers, engineers, and MLOps to industrialize and deliver scalable AI/ML solutions.
- Participate and contribute to the global data science community of practice.
- Be accountable and responsible for the robustness of the AI solution.
- Apply responsible AI frameworks and governance best practices, including monitoring, explainability, trustworthiness, and ethics.
- Mentor junior data scientists and analysts, providing guidance in career development and technical growth.
- Experience in a healthcare company is a strong plus.
- Experience in IoT and time-series forecasting is a plus.
About the company
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Get referred to Sanofi
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
- June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
- Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.
What critics are saying
- Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
- Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
- Dupixent concentration makes 2030s patent loss an existential revenue shock.
What makes Sanofi unique
- Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
- October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
- Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.
Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...
Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)